Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 5,097

Document Document Title
WO/2018/125880A1
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.  
WO/2018/115181A1
The present invention relates to novel salts and physical forms of ivabradine, methods for their formation, and uses thereof, such as in the treatment of myocardial ischemia and the like.  
WO/2018/119362A2
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2018/105572A1
The present invention is a method for producing ε-caprolactam via adipamide that serves as an intermediate. This method for producing ε-caprolactam is characterized by comprising a lactamization step wherein adipamide produced from a s...  
WO/2018/076108A1
ABSTRACT In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neuro...  
WO/2018/075608A1
The present invention relates to use of pyrimido-diazepinone compounds that are able to modulate protein kinases such as doublecortin-like kinase (DCLK1) and doublecortin-like kinase 2 (DCLK2), which are members of serine/threonine-prote...  
WO/2018/053240A1
Disclosed herein are compounds useful for modulating the mu-opioid receptor ("MOR") and/or delta-opioid receptor ("DOR"), and methods of using these compounds to treat diseases and conditions, such as pain. In particular, disclosed herei...  
WO/2018/047983A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X, Y, Z, D, R1, R2, R3, R4, R12, R15nd R16 are as defined in the specification, a process for their preparation, pharmaceut...  
WO/2018/022802A1
The invention provides antifungal compounds, antifungal compositions, and intermediates for the preparation of antifungal compounds and antifungal compositions. The invention also provides methods of inhibiting fungi and methods of treat...  
WO/2018/002847A1
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, aza-substituted triterpenoid compounds that possess unique antiviral activity are provided as HIV matu...  
WO/2017/216299A1
The object of the present invention are compounds comprising at least one donor group and at least one acceptor group, as described herein, which are characterized by a pronounced CT character. The invention also relates to the use there...  
WO/2017/213977A1
The present invention relates to methods for the treatment or prevention of symptoms associated with trauma and stressor-related disorders, in which exposure to a traumatic or stressful event is listed explicitly as a diagnostic criterio...  
WO/2017/202703A1
This invention relates to new benzazepine dicarboxamide compounds of the formula (I) wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agon...  
WO/2017/202704A1
This invention relates to new benzazepine dicarboxamide compounds of the formula (I) wherein R1 to R 3 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR ago...  
WO/2017/197045A1
A highly convergent biomimetic synthesis of a complex polycyclic scaffold has been successfully implemented. From these efforts, compounds having a structure of Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer ...  
WO/2017/173458A1
An object of the present invention to provide therapeutic compositions and methods for the prevention and/or treatment of airway obstructive disorders that involve bronchial hyper-responsiveness (BHR), asthma, horse asthma, airway remode...  
WO/2017/155686A1
An acyclic fluorinated compound of formula (I) is amine -containing acyclic hydrofluoroethers. The acyclic fluorinated compound is useful as heat transfer, solvent cleaning, fire extinguishing agents and electrolyte solvents and additives.  
WO/2017/147098A1
The disclosure provides methods for deoxydehydration of sugar-based derivatives using hydrogen gas as a reducing agent.  
WO/2017/147098A8
The disclosure provides methods for deoxydehydration of sugar-based derivatives using hydrogen gas as a reducing agent.  
WO/2017/144393A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting 2-substituted 5-(phenyl)-1,2-dihydro-3H-3-benzazepine-3-carboxamide derivatives of general formula (I), where R...  
WO/2017/144598A1
Cocrystals of Lorcaserin hydrochloride and an organic diacid, in particular with (+)-di-p- toluoyl-D-tartaric acid; (+)-camphoric acid; and oxalic acid, processes for their preparation, their therapeutical indications, as well as, pharma...  
WO/2017/131149A1
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...  
WO/2017/121645A1
The present invention relates to 3-ethyl-3-phenylazepane derivatives having dual pharmacological activity towards both the sigma (σ) receptor and the μ- opioid receptor, to processes of preparation of such compounds, to pharmaceutical ...  
WO/2017/123884A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceut...  
WO/2017/123884A8
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceut...  
WO/2017/108152A1
The present invention relates to compounds according to formula (I), which are suitable for use in electronic devices, preferably organic electroluminescent devices.  
WO/2017/111176A1
Synthesis of an organic compound with chirality is an important technique in the fields of medicines, pesticides, health foods, etc. However, catalysts to be used for such synthesis are produced from expensive starting materials and, fur...  
WO/2017/075264A8
The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorde...  
WO/2017/075264A1
The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorde...  
WO/2017/070793A1
The present application relates to novel fluorinated heterocycle derivatives or compounds of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention ...  
WO/2017/053776A1
Glucosepane is a structurally complex protein post-translational modification (PTM) believed to exist in all living organisms. Research in humans suggests that glucosepane plays a critical role in the pathophysiology of both diabetes and...  
WO/2017/046112A1
This invention relates to novel sulfinylphenyl or sulfonimidoylphenyl benzazepine compounds of the formula (I) wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts there...  
WO/2017/046707A1
Compounds of Formula (I) are disclosed and methods of treating viral infections with compositions comprising such compounds.  
WO/2017/043560A1
Abstract: Disclosed is a method for producing ε-caprolactam from 3-oxoadipic acid, which is suitable as a biomass resource. The method for producing ε-caprolactam includes a step 1 for mixing at least one selected from the group compri...  
WO/2017/044516A1
The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined ...  
WO/2017/038656A1
The present invention provides: a novel tetrahydroazepine compound; and a method for producing the tetrahydroazepine compound. The present invention relates to: a tetrahydroazepine compound represented by general formula (10) (wherein R1...  
WO/2017/023679A1
Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing fo...  
WO/2017/021466A1
The present invention relates to a process for the preparation of a solid form of ivabradine hydrochloride by reduction of Compound 2 or a salt thereof in an aqueous solvent followed by extraction of ivabradine wherein the extraction com...  
WO/2017/012890A1
The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.  
WO/2017/011371A1
The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins w...  
WO/2017/004522A1
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2016/207082A1
The invention relates to haloalkylsulphonamide derivatives of the formula (I) wherein A, W, X, m, n, p, R, R1, R2, R5, R6, R7and R8 are as defined in the specification. Furthermore, the present invention relates to processes for making c...  
WO/2016/197398A1
Disclosed are a sulfonic acid inner salt compound of amidine and a preparation method therefor. The product of a sulfonic acid inner salt of amidine is obtained and synthesized by adopting an o-aminobenzenesulfonyl chloride compound and ...  
WO/2016/193452A1
The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.  
WO/2016/193386A2
A method for the preparation of purified ivabradine and salts thereof, a method for the purification of ivabradine and salts thereof, a new reactant used in said methods and the use of said reactant for the preparation of ivabradine.  
WO/2016/193386A3
A method for the preparation of purified ivabradine and salts thereof, a method for the purification of ivabradine and salts thereof, a new reactant used in said methods and the use of said reactant for the preparation of ivabradine.  
WO/2016/187339A1
Galantamine and its pharmaceutically acceptable salts are of use in treating persons meeting criteria for having a risk of developing Alzheimer's type dementia, before dementia occurs by reducing the decline of Aβ amyloid in CSF or the ...  
WO/2016/182850A1
The present invention relates to methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof. The resulting products are useful in the treatment of proliferative diseases and infectious diseases.  
WO/2016/164565A1
A substituted trans-cycloheptene according to formula (I); wherein : a) Z and L are each selected from the group consisting of SiR1R2, CH2, CHOH, and CHR2; R1 is phenyl or CH3; R2 is phenyl, CH3, (CH2)nCN, or (CH2)nOH, wherein n is an in...  
WO/2016/160579A1
This invention provides efficient and scalable enantioselective methods that yield 2-alkyl-2-allylcycloalkyanone compounds with quaternary stereogenic centers. Methods include the method for the preparation of a compound of formula (I), ...  

Matches 1 - 50 out of 5,097